---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041285"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:19:15.167878+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Frequency Therapeutics Q2 net loss narrows to $10.8M; merger with Korro Bio expected Q4 2023

## Summary
- Net loss of $10.8M for Q2 2023, down from $21.3M in Q2 2022 due to hearing program discontinuation.
- Cash, equivalents and marketable securities $46.5M; all outstanding debt prepaid in April.
- Definitive merger agreement with Korro Bio, expected close Q4 2023; combined company to trade as 'KRRO'.
- Stockholders may receive CVR for remyelination program if not monetized before merger close.
- R&D expenses fell to $4.6M from $13.3M; G&A expenses $7.2M vs $8.0M.

## SEC filing metadata
- accession: 0000950170-23-041285
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/freq-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041285
- JSON: https://secwatch.observer/filing/0000950170-23-041285.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041285.txt

## Key facts
- Earnings Releases
  Korro Bio, Inc. reported the six months ended June 30, 2023 results: net income $30.3 million.
  - Period: the six months ended June 30, 2023
  - Net income: $30.3 million
  - Result: reported results
  source text: Net loss was $30.3 million for the six months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm
- Earnings Releases
  Korro Bio, Inc. reported the three months ended June 30, 2023 results: net income $10.8 million.
  - Period: the three months ended June 30, 2023
  - Net income: $10.8 million
  - Result: reported results
  source text: Net loss was $10.8 million for the three months ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017023041285/0000950170-23-041285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.